Why the study?
Protamine is used to reverse heparin and reduce post-TAVR bleeding, but concerns about risks such as valve thrombosis and stroke remain.
Does protamine reduce major bleeding complications in patients undergoing TF-TAVR?
Does protamine reduce major bleeding complications in patients undergoing TF-TAVR?
Answers are grounded in this paper and cite their sources.
Protamine appears safe for heparin reversal post-TAVR without increasing stroke risk, but did not significantly reduce major bleeding in this meta-analysis.
Transfemoral Trans-catheter Aortic Valve Replacement (TF-TAVR) is a safe alternative to surgical aortic valve replacement (SAVR). Protamine is used to reverse heparin and reduce post-TAVR bleeding, but concerns about risks like valve thrombosis and stroke remain. This systematic review and meta-analysis, following PRISMA guidelines, found no statistically significant difference in major bleeding complications between the protamine and control groups [(3.0 % vs. 14.4 %); RR: 0.56; P = 0.16]. No differences were noted in life-threatening bleeding, blood transfusions, 30-day mortality, or stroke. Protamine appears safe post-TAVR without increasing stroke risk, but its effectiveness in reducing bleeding needs further investigation through a multicentric randomized study.
No takes yet. Share an insight, caveat, or question.
Kumaraguruparan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: